Additionally, the adoption of a national HCC surveillance programme that combines the use of AFP and PIVKA-II, alongside diagnostic algorithms like GAAD, would be both cost-effective and practical in the short term. The gene discussed is AFP; the disease is hepatocellular carcinoma.